Postpartum Depression: From Molecular Mechanisms to Clinical Management – A State-of-the-Art Review for the Obstetrician
DOI:
https://doi.org/10.12775/JEHS.2026.90.69957Keywords
Postpartum depression, allopregnanolone, neuroinflammation, GABA-A receptor, zuranolone, sertralineAbstract
Background. Postpartum depression (PPD) is a common childbirth complication, affecting an estimated 17.2% of women worldwide. Unlike the short-lived “baby blues,” PPD is a unique neurobiological illness defined by an inability to adapt synaptically to reproductive hormone withdrawal. It is the most common cause of maternal suicide, and the offspring of PPD mothers also suffer long-lasting cognitive and emotional impairments.
Aim. Our objective was to review the pathophysiology of PPD (with special emphasis on the GABAergic and immuno-inflammatory hypotheses), screening procedures and to outline a “stepped-care” management algorithm, including new neuroactive steroids.
Material and Methods. A systematic literature search was conducted using PubMed/MEDLINE, Embase, and Cochrane databases (Jan 2010 – Dec 2024). We prioritized meta-analyses, randomized controlled trials (RCTs), and guidelines from major obstetric societies (ACOG, RCOG).
Results. There is evidence for current hypothesis of rapid withdrawal of allopregnanolone as trigger of the development of symptoms that do not initiate the adequate GABA-A receptor reorganization in vulnerable women. Other mechanisms include HPA axis dysregulation and inflammation-induced tryptophan depletion. The gold standard for screening remains the Edinburgh Postnatal Depression Scale (EPDS) Sensitivity: 86%). Pharmacologic treatment has significantly progressed: Sertraline remains the first-line SSRI due to safety in lactation, but the FDA approval of Zuranolone (2023) provides a mechanism-specific, rapid-acting therapeutic option addressing the underlying hormonal dysregulation.
Conclusions. Obstetricians are the primary gatekeepers for maternal mental health. Preparation of obstetricians to identify women at higher risk and to treat with pharmacotherapy is an essential part of contemporary obstetric practice.
References
[1]American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR). 5th ed. Washington, DC: APA; 2022. https://doi.org/10.1176/appi.books.9780890425787
[2]Wang Z, Liu J, Shuai H, et al. Mapping global prevalence of depression among postpartum women. Transl Psychiatry. 2021;11(1):543. https://doi.org/10.1038/s41398-021-01663-6
[3]Luca DL, Garlow N, Staatz C, et al. Societal Costs of Untreated Perinatal Mood and Anxiety Disorders in the United States. Mathematica Policy Research. 2019. https://www.mathematica.org/publications/societal-costs-of-untreated-perinatal-mood-and-anxiety-disorders-in-the-united-states
[4]Trost SL, Beauregard J, Njie F, et al. Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees in 36 US States. CDC. 2022. https://www.cdc.gov/maternal-mortality/php/data-research/mmrc-2017-2019.htm l
[5]Wisner KL, Sit DK, McShea MC, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013;70(5):490-498. https://doi.org/10.1001/jamapsychiatry.2013.87
[6]Maguire J. Neuroactive steroids and GABAergic involvement in the neurobiology of postpartum depression. Front Cell Neurosci. 2019;13:23. https://doi.org/10.3389/fncel.2019.00023
[7]Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. Am J Psychiatry. 2023;180(9):668-675. https://doi.org/10.1176/appi.ajp.20220785
[8]Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):676-692. https://doi.org/10.1016/j.pnpbp.2010.05.008
[9]Osborne LM, Monk C. Perinatal depression—the fourth inflammatory morbidity of pregnancy? Psychoneuroendocrinology. 2013;38(10):1929-1952. https://doi.org/10.1016/j.psyneuen.2013.03.019
[10]Iliadis SI, Koulouris P, Gingnell M, et al. Personality and salivary cortisol in women with symptoms of postpartum depression. Arch Womens Ment Health. 2015;18(6):815-823. https://doi.org/10.1007/s00737-015-0524-7
[11]Guintivano J, Arad M, Gould TD, et al. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol Psychiatry. 2014;19(5):560-567. https://doi.org/10.1038/mp.2013.62
[12]Beck CT. Predictors of postpartum depression: an update. Nurs Res. 2001;50(5):275-285. https://doi.org/10.1097/00006199-200109000-00004
[13]Dekel S, Stuebe C, Dishy G. Childbirth Induced Posttraumatic Stress Syndrome: A Systematic Review of Prevalence and Risk Factors. Front Psychol. 2017;8:560. https://doi.org/10.3389/fpsyg.2017.00560
[14]Dias CC, Figueiredo B. Breastfeeding and depression: a systematic review of the literature. J Affect Disord. 2015;171:142-154. https://doi.org/10.1016/j.jad.2014.09.022
[15]Yim IS, Tanner Stapleton LR, Guardino CM, et al. Biological and psychosocial predictors of postpartum depression: systematic review and call for integration. Annu Rev Clin Psychol. 2015;11:99-137. https://doi.org/10.1146/annurev-clinpsy-101414-020426
[16]Levis B, Benedetti A, Thombs BD. Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression. BMJ. 2020;371:m4022. https://doi.org/10.1136/bmj.m4022
[17]Earls MF; AAP Committee on Psychosocial Aspects. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics. 2010;126(5):1032-1039. https://doi.org/10.1542/peds.2010-2548
[18]Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: Use of Antidepressants in Breastfeeding Mothers. Breastfeed Med. 2015;10(6):290-299. https://doi.org/10.1089/bfm.2015.29002.nks
[19]Deligiannidis KM, Lasser R, Gunduz-Bruce H, et al. Zuranolone for the Treatment of Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(9):951-959. https://doi.org/10.1001/jamapsychiatry.2021.1559
[20]Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392(10152):1058-1070. https://doi.org/10.1016/S0140-6736(18)31551-4
[21]Wisner KL, Perel JM, Peindl KS, et al. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry. 2004;161(7):1290-1292. https://doi.org/10.1176/appi.ajp.161.7.1290
[22]Sparling TM, Henschke N, Nesbitt RC, Gabrysch S. The role of diet and nutritional supplementation in perinatal depression: a systematic review. Matern Child Nutr. 2017;13(1). https://doi.org/10.1111/mcn.12235
[23]Byatt N, Straus J, Stopa A, et al. Massachusetts Child Psychiatry Access Program for Moms: Utilization and Quality Assessment. Obstet Gynecol. 2018;132(2):345-353. https://doi.org/10.1097/AOG.0000000000002733
[24]Howard LM, Khalifeh H. Perinatal mental health: a review of progress and challenges. World Psychiatry. 2020;19(3):313-327. https://doi.org/10.1002/wps.20769
[25]Putnam KT, Wilcox M, Robertson-Blackmore E, et al. Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. Lancet Psychiatry. 2017;4(6):477-485. https://doi.org/10.1016/S2215-0366(17)30136-0
[26]Silverman ME, Reichenberg A, Savitz DA, et al. The risk factors for postpartum depression: A population-based study. Depress Anxiety. 2017;34(2):178-187. https://doi.org/10.1002/da.22597
[27]Battle CL, Zlotnick C, Miller IW, et al. Clinical characteristics of perinatal bipolar disorder. Bipolar Disord. 2014. https://doi.org/10.1111/bdi.12151
[28]Payne JL, Maguire J. Pathophysiological mechanisms implicated in postpartum depression. Front Neuroendocrinol. 2019;52:165-180. https://doi.org/10.1016/j.yfrne.2018.12.001
[29]Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017. https://doi.org/10.1016/S0140-6736(17)31264-6
[30]ACOG Committee Opinion No. 757: Screening for Perinatal Depression. Obstet Gynecol. 2018. https://doi.org/10.1097/AOG.0000000000002927
[31]O'Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol. 2013;9:379-407. https://doi.org/10.1146/annurev-clinpsy-050212-185612
[32]Stewart DE, Vigod S. Postpartum Depression. N Engl J Med. 2016;375(22):2177-2186. https://doi.org/10.1056/NEJMcp1607649
[33]Shorey S, Chee CYI, Ng ED, et al. Prevalence and incidence of postpartum depression among healthy mothers: A systematic review and meta-analysis. J Psychiatr Res. 2018;104:235-248. https://doi.org/10.1016/j.jpsychires.2018.08.001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Maja Wojcieszak, Anna Gęborys, Joanna Kania, Alicja Maziarczyk, Jakub Lambach, Kacper Kutnik, Weronika Woźnica, Julia Dąbrowska, Michał Białogłowski, Katarzyna Mazurek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 14
Number of citations: 0
